Potential effectiveness of Ospemifene on Detrusor Overactivity in patients with vaginal atrophy

The influence of estrogens on lower urinary tract function and how their insufficiency is associated with the genitourinary syndrome of menopause (GSM) is well known. A recent meta-analysis confirmed that women who were treated with vaginal estrogen at the recommended doses had an improvement in both genital and urinary symptoms 1. Ospemifene, a selective estrogen receptor modulator recently approved by the FDA for the treatment of postmenopausal women experiencing moderate-to-severe dyspareunia is an alternative to local estrogen therapy2.

Source: Maturitas - May 9, 2020 Category: Primary Care Authors: Lorenzo Novara, Luca Giuseppe Sgro, Matteo Mancarella, Roberto Capece, Elena Canale, Nicoletta Biglia Source Type: research